The following article will
give the reader a comprehensive overview of the FDA’s communications to date concerning
surgical mesh when used transvaginally in pelvic organ prolapse surgeries. The
article An Appraisal of the Food and Drug
Administration Warning and Urogynecologic Surgical Mesh, published in the
Current Urology Reports (2012, 13:231-239) gives an overview of the FDA’s
conclusions regarding the use of surgical mesh in POP surgeries. The first Public
Health Notification issued by the FDA came out in 2008 after over a thousand
women submitted adverse health reports following transvaginal surgery using
gynecologic mesh. Three years later the FDA issued an update to that report
regarding the safety and effectiveness of mesh in POP surgery. At this time the
agency reviewed the currently available safety data and scientific research on
gynecologic mesh.
This article states that it is
estimated that over a third of pelvic organ prolapse surgeries implement
surgical mesh and that 75% of all these surgeries were done transvaginally.
These numbers come from the over 300,000 women who undergo pelvic organ
prolapse surgery annually in the U.S. and over 260,000 who undergo a surgical
procedure for stress urinary incontinence. The FDA states that as far as SUI
surgeries go, “more than 80% were done
transvaginally with mesh.” The FDA’s conclusion is that although POP
surgery done transvaginally may restore the woman’s body anatomically, there
are few if any benefits over surgeries which do not implement urogynecologic
mesh.